

# NAVIGATING ADVANCEMENTS IN DIAGNOSIS & TREATMENT OF AXIAL SPONDYLOARTHRITIS



This activity is supported by an educational grant from Eli Lilly.



## FDA-approved Treatments

Agent	FDA approval	Dosing	Administration Frequency	Serious Adverse Events (SAEs)
<b>TNFa inhibitors</b>				
Adalimumab	2006	40 mg by subc injection every other week	Every other week	<b>Common AEs:</b> Nasopharyngitis, injection-site reactions, headache <b>SAEs:</b> TB, invasive fungal, and other opportunistic infections
Etanercept	2003	50 mg once weekly	Weekly	<b>SAEs:</b> Increased risk of serious infection, including TB, bacterial sepsis, and invasive fungal infections
Certolizumab pegol (CZP) for nr-axSpA	2019	400 mg (given as 2 subc injections of 200 mg) initially, and at weeks 2 and 4; <b>maintenance</b> regimen 200 mg every other week or 400 mg every 4 weeks	Every 2 or 4 weeks, depending on dose	<b>SAEs:</b> Increased risk of serious infection, including TB, bacterial sepsis, and invasive fungal infections
Golimumab	2017	50 mg by subc injection once a month	Monthly	<b>SAEs:</b> Increased risk of serious infection, including TB, bacterial sepsis, and invasive fungal infections
Infliximab <sup>35</sup>	2004	5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks	Every 6 weeks	<b>Common AEs:</b> Fever, extreme tiredness, flu-like symptoms, skin rashes, cough, stomach pain <b>SAEs:</b> Increased risk of serious infection, including TB, bacterial sepsis, and invasive fungal infections
<b>Interleukin-17A</b>				
Ixekizumab for nr-axSpA	2019	80 mg/mL by subc injection every 4 weeks	Every 4 weeks	<b>Common AEs:</b> Injection site reactions, upper respiratory infections, nausea, fungal skin infections <b>SAEs:</b> increased risk for infection, including TB, IBD, hypersensitivity
Secukinumab for nr-axSpA	2020	150 mg without loading dose every 4 weeks	Every 4 weeks	<b>SAEs:</b> Serious infections have occurred, including TB, IBD, hypersensitivity